Company news

Eledon Pharmaceuticals, Inc. news in 2022

Eledon Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

November 13, 2022

Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS

October 23, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

September 5, 2022

Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results

August 10, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

July 31, 2022

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation

July 17, 2022

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation

June 8, 2022

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

May 30, 2022

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

May 11, 2022

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

May 8, 2022

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

April 13, 2022

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

March 23, 2022

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook

February 13, 2022

Calls in 2022

Decks in 2022